10-Q: Quarterly report pursuant to Section 13 or 15(d)
Published on August 23, 2010
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
For the quarterly period ended June 30, 2010
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
For the transition period from to
Commission File Number: 001-34632
CryoPort, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Nevada (State or Other Jurisdiction of Incorporation or Organization) |
88-0313393 (IRS Employer Identification No.) |
|
20382 BARENTS SEA CIRCLE, LAKE FOREST, CA (Address of Principal Executive Offices) |
92630 (Zip Code) |
Registrants Telephone Number, Including Area Code: (949) 470-2300
Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. þ Yes o No
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files).
o Yes o No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):
Large accelerated filer o | Accelerated filer o | Non-accelerated filer o (Do not check if a smaller reporting company) |
Smaller reporting company þ |
Indicate by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). o Yes þ No
As of August 3, 2010 the Company had 8,150,255 shares of its $0.001 par value common stock issued
and outstanding. As discussed in Note 9 of the accompanying unaudited condensed consolidated financial
statements, on August 20, 2010, the Company completed a private placement of its securities to
institutional and accredited investors resulting in the issuance of
4,574,573 shares of common
stock and other securities.
TABLE OF CONTENTS
Page | ||||||||
3 | ||||||||
3 | ||||||||
3 | ||||||||
4 | ||||||||
5 | ||||||||
7 | ||||||||
24 | ||||||||
27 | ||||||||
28 | ||||||||
29 | ||||||||
29 | ||||||||
29 | ||||||||
29 | ||||||||
29 | ||||||||
29 | ||||||||
30 | ||||||||
31 | ||||||||
Exhibit 31.1 | ||||||||
Exhibit 31.2 | ||||||||
Exhibit 32.1 |
2
Table of Contents
PART I FINANCIAL INFORMATION
ITEM 1. | FINANCIAL STATEMENTS |
CRYOPORT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, | March 31, | ||||||||||
2010 | 2010 | ||||||||||
(unaudited) | |||||||||||
ASSETS |
|||||||||||
Current assets: |
|||||||||||
Cash and cash equivalents |
$ | 2,097,202 | $ | 3,629,886 | |||||||
Restricted cash |
90,630 | 90,404 | |||||||||
Accounts receivable, net of allowances of $2,000 at June 30, 2010 and $1,500 at March 31, 2010 |
32,816 | 81,036 | |||||||||
Other current assets |
102,099 | 104,014 | |||||||||
Total current assets |
2,322,747 | 3,905,340 | |||||||||
Property and equipment, net |
734,996 | 559,241 | |||||||||
Intangible assets, net |
335,894 | 311,965 | |||||||||
Deferred financing costs |
10,000 | | |||||||||
Total assets |
$ | 3,403,637 | $ | 4,776,546 | |||||||
LIABILITIES AND STOCKHOLDERS DEFICIT |
|||||||||||
Current liabilities: |
|||||||||||
Accounts payable |
$ | 604,141 | $ | 823,653 | |||||||
Accrued compensation and related expenses |
321,295 | 312,002 | |||||||||
Current portion of convertible debentures payable, net of discount |
345,193 | 200,000 | |||||||||
Line of credit and accrued interest |
90,375 | 90,388 | |||||||||
Current portion of related party notes payable |
150,000 | 150,000 | |||||||||
Derivative liabilities |
217,835 | 334,363 | |||||||||
Total current liabilities |
1,728,839 | 1,910,406 | |||||||||
Related party notes payable and accrued interest, net of current portion |
1,463,280 | 1,478,256 | |||||||||
Convertible debentures payable, net of current portion and discount |
2,278,831 | 2,302,459 | |||||||||
Total liabilities |
5,470,950 | 5,691,121 | |||||||||
Commitments and Contingencies |
|||||||||||
Stockholders deficit: |
|||||||||||
Common stock, $0.001 par value; 250,000,000 shares authorized; 8,150,255 and 8,136,619 shares issued and outstanding at June 30, 2010 and
March 31, 2010, respectively |
8,150 | 8,137 | |||||||||
Additional paid-in capital |
45,197,150 | 45,021,097 | |||||||||
Accumulated deficit |
(47,272,613 | ) | (45,943,809 | ) | |||||||
Total stockholders deficit |
(2,067,313 | ) | (914,575 | ) | |||||||
Total liabilities and stockholders deficit |
$ | 3,403,637 | $ | 4,776,546 | |||||||
See accompanying notes to unaudited condensed consolidated financial statements
3
Table of Contents
CRYOPORT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
For The Three Months Ended | ||||||||
June 30, | ||||||||
2010 | 2009 | |||||||
Revenues |
$ | 151,460 | $ | 13,703 | ||||
Cost of revenues |
394,535 | 149,177 | ||||||
Gross loss |
(243,075 | ) | (135,474 | ) | ||||
Costs and expenses: |
||||||||
Selling, general and administrative |
943,265 | 728,309 | ||||||
Research and development |
122,121 | 87,725 | ||||||
Total costs and expenses |
1,065,386 | 816,034 | ||||||
Loss from operations |
(1,308,461 | ) | (951,508 | ) | ||||
Other (expense) income: |
||||||||
Interest income |
3,437 | 1,481 | ||||||
Interest expense |
(138,708 | ) | (2,533,197 | ) | ||||
Loss on sale of property and equipment |
| (797 | ) | |||||
Change in fair value of derivative liabilities |
116,528 | 3,134,298 | ||||||
Total other (expense) income, net |
(18,743 | ) | 601,785 | |||||
Loss before income taxes |
(1,327,204 | ) | (349,723 | ) | ||||
Income taxes |
1,600 | | ||||||
Net loss |
$ | (1,328,804 | ) | $ | (349,723 | ) | ||
Net loss per common share, basic and diluted |
$ | (0.16 | ) | $ | (0.08 | ) | ||
Basic and diluted weighted average common shares outstanding |
8,146,477 | 4,293,965 | ||||||
See accompanying notes to unaudited condensed consolidated financial statements
4
Table of Contents
CRYOPORT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
For The Three Months Ended | ||||||||
June 30, | ||||||||
2010 | 2009 | |||||||
Operating Activities |
||||||||
Net loss |
$ | (1,328,804 | ) | $ | (349,723 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Depreciation and amortization |
52,935 | 31,502 | ||||||
Amortization of deferred financing costs |
| 7,904 | ||||||
Amortization of debt discount |
121,565 | 2,268,690 | ||||||
Stock issued to consultants |
| 106,807 | ||||||
Fair value of stock options and warrants issued to consultants, employees and directors |
152,067 | 272,312 | ||||||
Change in fair value of derivative instruments |
(116,528 | ) | (3,134,298 | ) | ||||
Loss on sale of assets |
| 797 | ||||||
Loss on disposal of Cryogenic shippers |
2,613 | | ||||||
Interest accrued on restricted cash |
(226 | ) | (597 | ) | ||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
48,220 | (5,009 | ) | |||||
Inventory |
| 17,685 | ||||||
Prepaid expenses and other assets |
1,915 | 3,650 | ||||||
Accounts payable |
(205,513 | ) | 102,986 | |||||
Accrued compensation and related expense |
9,293 | 14,928 | ||||||
Accrued interest |
15,011 | 156,406 | ||||||
Net cash used in operating activities |
(1,247,452 | ) | (505,960 | ) | ||||
Investing Activities |
||||||||
Purchases of intangibles |
(44,381 | ) | (18,020 | ) | ||||
Purchases of property and equipment |
(210,851 | ) | (9,766 | ) | ||||
Net cash used in investing activities |
(255,232 | ) | (27,786 | ) | ||||
Financing Activities |
||||||||
Proceeds from borrowings under convertible notes |
| 926,500 | ||||||
Repayment of deferred financing costs |
| (55,590 | ) | |||||
Payment of related party notes payable |
(30,000 | ) | (30,000 | ) | ||||
Net cash (used in) provided by financing activities |
(30,000 | ) | 840,910 | |||||
Net change in cash and cash equivalents |
(1,532,684 | ) | 307,164 | |||||
Cash and cash equivalents, beginning of year |
3,629,886 | 249,758 | ||||||
Cash and cash equivalents, end of year |
$ | 2,097,202 | $ | 556,922 | ||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION |
||||||||
Cash paid during the year for: |
||||||||
Interest |
$ | 2,133 | $ | 1,976 | ||||
Income taxes |
$ | 1,600 | $ | | ||||
See accompanying notes to unaudited condensed consolidated financial statements
5
Table of Contents
CRYOPORT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
For The Three Months Ended | ||||||||
June 30, | ||||||||
2010 | 2009 | |||||||
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES: |
||||||||
Deferred financing costs in connection with equity financing |
$ | 10,000 | $ | | ||||
Estimated fair value of shares issued for services |
$ | 23,999 | $ | | ||||
Debt discount in connection with convertible debt financing |
$ | | $ | 823,209 | ||||
Conversion of debt and accrued interest to common stock |
$ | | $ | 846,632 | ||||
Cashless exercise of warrants and stock options |
$ | | $ | 110 | ||||
Cumulative effect of accounting change to debt discount for derivative liabilities |
$ | | $ | 2,595,095 | ||||
Cumulative effect of accounting change to accumulated deficit for derivative liabilities |
$ | | $ | 9,657,893 | ||||
Cumulative
effect of accounting change to additional paid-in capital for derivative liabilities |
$ | | $ | 4,217,730 | ||||
Estimated fair value of debt-related derivative liabilities reclassified from liabilities to additional paid-in capital |
$ | | $ | 593,303 | ||||
See accompanying notes to unaudited condensed consolidated financial statements
6
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note
1. Managements Representation and Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared by
CryoPort, Inc. (the Company) in accordance with accounting principles generally accepted in the
United States of America (U.S. GAAP) for interim financial information, and pursuant to the
instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the Securities and
Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes
required by GAAP for complete financial statement presentation. However, the Company believes that
the disclosures are adequate to make the information presented not misleading. In the opinion of
management, all adjustments (consisting primarily of normal recurring accruals) considered
necessary for a fair presentation have been included.
Operating results for the three months ended June 30, 2010 are not necessarily indicative of
the results that may be expected for the year ending March 31, 2011. The unaudited condensed
consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and related notes thereto included in the Companys Annual Report on Form 10-K
for the fiscal year ended March 31, 2010.
The Company has evaluated subsequent events through the date of this filing, and determined
that no subsequent events have occurred that would require recognition in the unaudited condensed
consolidated financial statements or disclosure in the notes thereto other than as disclosed in the
accompanying notes.
Note 2. Organization and Summary of Significant Accounting Policies
The Company
CryoPort, Inc. (the Company or we) is a provider of an innovative cold chain frozen
shipping system dedicated to providing superior, affordable cryogenic shipping solutions that
ensure the safety, status and temperature of high value, temperature sensitive materials. The
Company has developed cost-effective reusable cryogenic transport containers (referred to as a
shipper) capable of transporting biological, environmental and other temperature sensitive
materials at temperatures below 0° Celsius. These dry vapor shippers are one of the first
significant alternatives to using dry ice and achieve 10-plus day holding times compared to one to
two day holding times with dry ice (assuming no re-icing during transit). The Companys value
proposition comes from both providing safe transportation and an environmentally friendly, long
lasting shipper, and through its value-added services that offer a simple hassle-free solution for
its customers. These value-added services include an internet-based web portal that enables the
customer to conveniently initiate scheduling, shipping and tracking the progress and status of a
shipment, and provide in-transit temperature and custody transfer monitoring of the shipper. The
CryoPort service also provides a fully ready charged shipper containing all freight bills, customs
documents and regulatory paperwork for the entire journey of the shipper to its customers at their
pick up location.
The Companys principal focus has been the further development and commercial launch of
CryoPort Express® Portal, an innovative IT solution for shipping and tracking high-value specimens
through overnight shipping companies, and its CryoPort Express® Shipper, a dry vapor cryogenic
shipper for the transport of biological and pharmaceutical materials. A dry vapor cryogenic
shipper is a container that uses liquid nitrogen in dry vapor form, which is suspended inside a
vacuum insulated bottle as a refrigerant, to provide storage temperatures below minus 150° Celsius.
The dry vapor shipper is designed using innovative, proprietary, and patent pending technology
which prevents spillage of liquid nitrogen and pressure build up as the liquid nitrogen evaporates.
A proprietary foam retention system is employed to ensure that liquid nitrogen stays inside the
vacuum container, even when placed upside-down or on its side as is often the case when in the
custody of a shipping company. Biological specimens are stored in a specimen chamber, referred to
as a well, inside the container and refrigeration is provided by harmless cold nitrogen gas
evolving from the liquid nitrogen entrapped within the foam retention system surrounding the well.
Biological specimens transported using our cryogenic shipper can include clinical samples,
diagnostics, live cell pharmaceutical products (such as cancer vaccines, semen and embryos, and
infectious substances) and other items that require and/or are protected through continuous
exposure to frozen or cryogenic temperatures (less than minus 150 ° Celsius).
The Company recently entered into its first strategic relationship with a global courier on
January 13, 2010 when it signed an agreement with Federal Express Corporation (FedEx) pursuant to
which the Company will lease to FedEx such number of its cryogenic shippers that FedEx shall, from
time to time, order for FedExs customers. Under this agreement, FedEx has the right to and shall,
on a non-exclusive basis, promote market and sell transportation of the Companys shippers and its
related value-added goods and services, such as its data logger, web portal and planned CryoPort
Express® Smart Pak System.
7
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 2. Organization and Summary of Significant Accounting Policies, continued,
Going Concern
As reported in the Report of Independent Registered Public Accounting Firm on the Companys
March 31, 2010 and 2009 consolidated financial statements, the Company has incurred recurring
losses and negative cash flows from operations since inception. The Company has not generated
significant revenues from operations and has no assurance of any future significant revenues. The
Company generated revenues of $151,460, incurred a net loss of
$1,328,804 and used cash from operations of
$1,247,452 during the three months ended June 30, 2010. The Company
generated revenues of $117,956, incurred a net loss of $5,651,561 and
used cash from operations of $2,853,359 during the year ended March 31, 2010. These factors raise substantial
doubt about the Companys ability to continue as a going concern.
On February 25, 2010, the Company completed a public offering for net proceeds of
approximately $3,742,097. As a result of the public offering, the Company had aggregate cash and
cash equivalents of $2,097,202 as of June 30, 2010, which will be used to fund the working capital
required for minimal operations including limited shipper build up as well as limited sales efforts
to advance the Companys commercialization of the CryoPort Express® Shippers until additional
capital is obtained. On August 20, 2010, the Company completed a private placement to
institutional and accredited investors resulting in the issuance of
units consisting of 4,574,573
shares of common stock and warrants to purchase 4,574,573 shares of common stock at an exercise
price of $0.77 per share, for gross cash proceeds of $3,202,201 and
net cash proceeds of
$2,945,822. Each unit
consisting of one share, together with one warrant to purchase one share, was priced at $0.70.
Certain investors that had invested in the Companys public offering that was completed on February
25, 2010 were issued additional warrants with the same terms to purchase an aggregate of 445,001 shares of common stock
in connection with this private placement. Approximately $3,000,000
of the gross cash proceeds were disbursed from escrow on August 20, 2010,
with the balance expected to be disbursed within five business days. Management has estimated that cash on hand as of June 30, 2010 plus the additional cash
from the private placement, will be sufficient to allow the Company to continue its operations only
into the third quarter of fiscal 2011. The Companys management recognizes that the Company must
obtain additional capital for the achievement of sustained profitable operations. Managements
plans include obtaining additional capital through equity and debt funding sources; however, no
assurance can be given that additional capital, when needed, will be available when required or upon
terms acceptable to the Company.
Reverse Stock Split
On February 5, 2010, we effected a 10-for-1 reverse stock split of all of our issued and
outstanding shares of common stock (the Reverse Stock Split) by filing a Certificate of Amendment
to Amended and Restated Articles of Incorporation with the Secretary of State of Nevada. The par
value and number of authorized shares of our common stock remained unchanged. The number of shares
and per share amounts included in the unaudited condensed consolidated financial statements and the
accompanying notes have been adjusted to reflect the Reverse Stock Split retroactively. Unless
otherwise indicated, all references to number of shares, per share amounts and earnings per share
information contained in this report give effect to the Reverse Stock Split.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of CryoPort,
Inc. and its wholly owned subsidiary, CryoPort Systems, Inc. All intercompany accounts and
transactions have been eliminated.
8
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 2. Organization and Summary of Significant Accounting Policies, continued
Use of Estimates
The
preparation of condensed consolidated financial statements in
conformity with U.S. GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting periods. Actual
results could differ from estimated amounts. The Companys significant estimates include allowances
for doubtful accounts and sales returns, recoverability of long-lived assets, deferred tax assets
and their accompanying valuations, valuation of derivative liabilities and valuation of common
stock, warrants and stock options issued for products or services.
Fair Value of Financial Instruments
The Companys financial instruments consist of cash and cash equivalents, restricted cash,
accounts receivable, related-party notes payable, a line of credit, convertible notes payable,
accounts payable and accrued expenses. The carrying value for all such instruments approximates
fair value at June 30, 2010 and March 31, 2010. The difference between the fair value and recorded
values of the related party notes payable is not significant.
Cash and Cash Equivalents
The Company considers highly liquid investments with original maturities of 90 days or less to
be cash equivalents.
Concentration of Credit Risk
Cash and cash equivalents
The Company maintains its cash accounts in financial institutions. Accounts at these
institutions are insured by the Federal Deposit Insurance Corporation (FDIC). Effective October
3, 2008, the Emergency Economic Stabilization Act of 2008 raised the FDIC deposit coverage limits
to $250,000 per owner from $100,000 per owner through January 1, 2014. At June 30, 2010 and March
31, 2010, the Company had $1,953,062 (which exceeded the FDIC insurance limit) and $3,490,116,
respectively, of cash balances, including restricted cash. The Company performs ongoing evaluations
of these institutions to limit its concentration risk exposure.
Restricted cash
The Company has invested cash in a one year restricted certificate of deposit bearing interest
at 1% which serves as collateral for borrowings under a line of credit agreement (see Note 3). At
June 30, 2010 and March 31, 2010, the balance in the certificate of deposit was $90,630 and
$90,404, respectively.
Customers
The Company grants credit to customers within the United States of America and to a limited
number of international customers and does not require collateral. Revenues from international
customers are generally secured by advance payments except for a limited number of established
foreign customers. The Company generally requires advance or credit card payments for initial
revenues from new customers. The Companys ability to collect receivables is affected by economic
fluctuations in the geographic areas and industries served by the Company. Reserves for
uncollectible amounts are provided based on past experience and a specific analysis of the accounts
which management believes are sufficient. Accounts receivable at June 30, 2010 and March 31, 2010
are net of reserves for doubtful accounts of approximately $2,000 and $1,500, respectively.
Although the Company expects to collect amounts due, actual collections may differ from the
estimated amounts.
The Company has foreign revenues primarily in Europe, Canada, India and Australia. During
the three month periods ended June 30, 2010 and 2009, the Company had foreign sales of
approximately $57,000 and $1,000, respectively, which constituted approximately 38% and 7%,
respectively, of revenues.
9
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 2. Organization and Summary of Significant Accounting Policies, continued
The majority of the Companys customers are in the biotechnology, pharmaceutical and life
science industries. Consequently, there is a concentration of receivables within these industries,
which is subject to normal credit risk. At June 30,
2010, net revenues for the three months ended June 30, 2010 from BD Biosciences and CDx Holdings,
Inc. accounted for 13% and 63%, respectively, of our total revenues. At June 30, 2009, there were
no significant customer concentrations. The Company maintains reserves for bad debt and such
losses, in the aggregate, historically have not exceeded our estimates.
Inventory
Prior to our new business strategy inventories were stated at the lower of standard cost or
current estimated market value. Cost was determined using the standard cost method which
approximates the first-in, first-to-expire method.
In fiscal year 2010, the Company changed its operations and now provides shipping containers
to its customers and charges a fee in exchange for the use of the container. The Companys
arrangements are similar to the accounting standard for leases since they convey the right to use
the containers over a period of time. The Company retains title to the containers and provides its
customers the use of the container for a specified shipping cycle. At the culmination of the
customers shipping cycle, the container is returned to the Company. As a result, during the
quarter ended September 30, 2009, the Company reclassified the containers from inventory to fixed
assets upon commencement of the per-use container program.
Property and Equipment
Property
and equipment are recorded at cost. Cryogenic Shippers, which
comprise 80% of the Companys net property and equipment
balance, are depreciated using the
straight-line method over their estimated useful lives of three years. Equipment and furniture are
depreciated using the straight-line method over their estimated useful lives (generally three to
seven years) and leasehold improvements are amortized using the straight-line method over the
estimated useful life of the asset or the lease term, whichever is shorter. Equipment acquired
under capital leases is amortized over the estimated useful life of the assets or term of the
lease, whichever is shorter and included in depreciation expense.
Betterments, renewals and extraordinary repairs that extend the lives of the assets are
capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related
accumulated depreciation and amortization applicable to assets retired are removed from the
accounts, and the gain or loss on disposition is recognized in current operations.
Depreciation expense for property and equipment was $32,483 and $17,348 for the three months
ended June 30, 2010 and 2009, respectively.
10
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 2. Organization and Summary of Significant Accounting Policies, continued
Intangible Assets
Intangible assets are comprised of patents and trademarks and software development costs. The
Company capitalizes costs of obtaining patents and trademarks which are amortized, using the
straight-line method over their estimated useful life of five years. The Company capitalizes
certain costs related to software developed for internal use. Software development costs incurred
during the preliminary or maintenance project stages are expensed as incurred, while costs incurred
during the application development stage are capitalized and amortized using the straight-line
method over the estimated useful life of the software, which is five years. Capitalized costs
include purchased materials and costs of services including the valuation of warrants issued to
consultants.
Amortization expense for intangible assets for the three months ended June 30, 2010 and 2009
was $20,452 and $14,154, respectively. All of the Companys intangible assets are subject to
amortization.
Long-lived Assets
If indicators of impairment exist, we assess the recoverability of the affected long-lived
assets by determining whether the carrying value of such assets can be recovered through
undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such
impairment by comparing the fair value to the carrying value. We believe the future cash flows to
be received from the long-lived assets will exceed the assets carrying value, and accordingly, we
have not recognized any impairment losses at June 30, 2010 or March 31, 2010.
Deferred Financing Costs
Deferred financing costs represent costs incurred in connection with the issuance of the
convertible notes payable and private equity financing. Deferred financing costs are being
amortized over the term of the financing instrument on a straight-line basis, which approximates
the effective interest method, or netted against the gross proceeds received from equity financing.
During the three month periods ended June 30, 2010 and 2009, the Company capitalized deferred
financing costs of $10,000 and $55,590, respectively. During the three month periods ended June
30, 2010 and 2009, the Company amortized deferred financing costs of $0 and $7,904, respectively,
to interest expense.
Convertible Debentures
If a conversion feature of conventional convertible debt is not accounted for as a derivative
instrument and provides for a rate of conversion that is below market value, this feature is
characterized as a beneficial conversion feature (BCF). A BCF is recorded by the Company as a
debt discount. The convertible debt is recorded net of the discount related to the BCF. The
Company amortizes the discount to interest expense over the life of the debt using the effective
interest rate method.
Derivative Liabilities
Effective April 1, 2009, certain of the Companys issued and outstanding common stock purchase
warrants and embedded conversion features previously treated as equity pursuant to the derivative
treatment exemption were no longer afforded equity treatment, and the fair value of these common
stock purchase warrants and embedded conversion features, some of which have exercise price reset
features and some that were issued with convertible debt, was reclassified from equity to
liability status as if treated as derivative liabilities since their dates of issue. The common
stock purchase warrants were not issued with the intent of effectively hedging any future cash
flow, fair value of any asset, liability or any net investment in a foreign operation. The warrants
do not qualify for hedge accounting, and as such, all future changes in the fair value of these
warrants are recognized currently in earnings until such time as the warrants are exercised, expire
or the related rights have been waived. These common stock purchase warrants do not trade in an
active securities market, and as such, the Company estimates the fair value of these warrants using
the Black-Scholes option pricing model (see Note 6).
11
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 2. Organization and Summary of Significant Accounting Policies, continued
Supply Concentration Risks
The component parts for our products are primarily manufactured at third party manufacturing
facilities. The Company also has a warehouse at our corporate offices in Lake Forest, California,
where the Company is capable of manufacturing certain parts and fully assembles its products. Most
of the components that the Company uses in the manufacture of its products are available from more
than one qualified supplier. For some components, however, there are relatively few alternate
sources of supply and the establishment of additional or replacement suppliers may not be
accomplished immediately, however, the Company has identified alternate qualified suppliers which
the Company believes could replace existing suppliers. Should this occur, the Company believes that
with its current level of shippers and production rate the Company has enough components to cover a
maximum four to six week disruption gap in production.
Primary manufacturers used by us include Spaulding Composites Company, Peterson Spinning and
Stamping, Lydall Industrial Thermal Solutions, and Ludwig, Inc. There are no specific agreements
with any manufacturer nor are there any long term commitments to any manufacturer. The Company
believes that any of the manufactures currently used by it could be replaced within a short period
of time as none have a proprietary component or a substantial capital investment specific to its
products.
Revenue Recognition
The Company provides shipping containers to their customers and charges a fee in exchange for
the use of the shipper. The Companys arrangements are similar to the accounting standard for
leases since they convey the right to use the shippers over a period of time. The Company retains
title to the shippers and provides its customers the use of the shipper for a specified
shipping cycle. At the culmination of the customers shipping cycle, the shipper is returned to
the Company.
The Company recognizes revenue for the use of the shipper at the time of the delivery of the
shipper to the end user of the enclosed materials and at the time that collectibility is
reasonably certain.
Accounting for Shipping and Handling Revenue, Fees and Costs
The Company classifies amounts billed for shipping and handling as revenue. Shipping and
handling fees and costs are included in cost of sales.
Research and Development Expenses
Expenditures relating to research and development are expensed in the period incurred.
Research and development expenses to date have consisted primarily of costs associated with
continually improving the features of the CryoPort Express® System including the web based customer
service portal and the CryoPort Express® Shippers. Further, these efforts are expected to lead to
the introduction of shippers of varying sizes based on market requirements, constructed of lower
cost materials and utilizing high volume manufacturing methods that will make it practical to
provide the cryogenic packages offered by the CryoPort Express® System. Other research and
development effort has been directed toward improvements to the liquid nitrogen retention system to
render it more reliable in the general shipping environment and to the design of the outer
packaging. Alternative phase change materials in place of liquid nitrogen may be used to increase
the potential markets these shippers can serve such as ambient and 2-8°C markets.
12
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 2. Organization and Summary of Significant Accounting Policies, continued
Stock-based Compensation
The Company accounts for share-based payments to employees and directors in accordance with
share-based payment accounting guidance which requires all share-based payments to employees and
directors, including grants of employee stock options and warrants, to be recognized based upon their fair values. The fair value of
stock-based awards is estimated at grant date using the Black-Scholes option pricing model and the
portion that is ultimately expected to vest is recognized as compensation cost over the requisite
service period.
Since stock-based compensation is recognized only for those awards that are ultimately
expected to vest, the Company has applied an estimated forfeiture rate to unvested awards for the
purpose of calculating compensation cost. These estimates will be revised, if necessary, in future
periods if actual forfeitures differ from estimates. Changes in forfeiture estimates impact
compensation cost in the period in which the change in estimate occurs. The estimated forfeiture
rates at June 30, 2010 and March 31, 2010 was zero as the Company has not had a significant history
of forfeitures and does not expect forfeitures in the future.
Cash flows from the tax benefits resulting from tax deductions in excess of the compensation
cost recognized for those options or warrants are classified as financing cash flows. Due to the
Companys loss position, there were no such tax benefits during the three months ended June 30,
2010 and 2009.
Plan Descriptions
The Company maintains two stock option plans, the 2002 Stock Incentive Plan (the 2002 Plan)
and the 2009 Stock Incentive Plan (the 2009 Plan). The 2002 Plan provides for grants of incentive
stock options and nonqualified options to employees, directors and consultants of the Company to
purchase the Companys shares at the fair value, as determined by management and the board of
directors, of such shares on the grant date. The options are subject to various vesting conditions
and generally vest over a three-year period beginning on the grant date and have seven to ten-year
term. The 2002 Plan also provides for the granting of restricted shares of common stock subject to
vesting requirements. The Company is authorized to issue up to 500,000 shares under this plan and
has 391,936 shares available for future issuances as of June 30, 2010.
On October 9, 2009, the Companys stockholders approved and adopted the 2009 Plan, which
had previously been approved by the Companys Board of Directors on August 31, 2009. The 2009 Plan
provides for the grant of incentive stock options, nonqualified stock options, restricted stock
rights, restricted stock, performance share units, performance shares, performance cash awards,
stock appreciation rights, and stock grant awards (collectively, Awards) to employees, officers,
non-employee directors, consultants and independent contractors of the Company. The 2009 Plan also
permits the grant of awards that qualify for the performance-based compensation exception to the
$1,000,000 limitation on the deduction of compensation imposed by Section 162(m) of the Internal
Revenue Code. A total of 1,200,000 shares of the Companys common stock are authorized for the
granting of Awards under the 2009 Plan. The number of shares available for future Awards, as well
as the terms of outstanding Awards, is subject to adjustment as provided in the 2009 Plan for stock
splits, stock dividends, recapitalizations and other similar events. Awards may be granted under
the 2009 Plan until the sooner of October 9, 2019 or until all shares available for Awards under
the 2009 Plan have been purchased or acquired. As of June 30, 2010, the Company has 974,411 shares
available for future Awards under the Plan.
13
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 2. Organization and Summary of Significant Accounting Policies, continued
In addition to the stock options issued pursuant to the Companys two stock option plans, the
Company has granted warrants to employees, officers, non-employee directors, consultants and
independent contractors. The warrants are generally not subject to vesting requirements and have
ten-year terms. At June 30, 2010 there were 16,667 warrants outstanding subject to vesting
conditions.
Summary of Assumptions and Activity
The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based
compensation expense for all share-based payment awards. Determining the appropriate fair-value
model and calculating the fair value of stock-based awards at the grant date requires considerable
judgment, including estimating stock price volatility, expected option life and forfeiture rates.
The Company develops estimates based on historical data and market information, which can change
significantly over time. The Company used the following assumptions for stock options granted
during the three months ended June 30, 2010 and 2009:
June 30, | June 30, | |||||
2010 | 2009 | |||||
Stock options and warrants: |
||||||
Expected term (in years) |
3.50 6.00 | 5.00 | ||||
Expected volatility |
171% 177% | 197% | ||||
Risk-free interest rate |
1.74% 3.07% | 1.86% 2.71% | ||||
Expected dividends |
N/A | N/A |
A summary of employee and director options and warrant activity for the three month period
ended June 30, 2010 is presented below:
Weighted | ||||||||||||||||
Weighted | Average | |||||||||||||||
Average | Remaining | Aggregate | ||||||||||||||
Exercise | Contractual | Intrinsic | ||||||||||||||
Shares | Price | Term (Yrs.) | Value | |||||||||||||
Outstanding at April 1, 2010 |
555,203 | $ | 6.22 | 7.55 | ||||||||||||
Granted |
36,800 | $ | 1.93 | | ||||||||||||
Exercised |
| $ | | | ||||||||||||
Forfeited |
| $ | | | ||||||||||||
Outstanding and expected to vest at June 30, 2010 |
592,003 | $ | 5.95 | 7.37 | $ | 17,558 | ||||||||||
Exercisable at June 30, 2010 |
409,959 | $ | 7.09 | 6.91 | $ | 17,558 | ||||||||||
14
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 2. Organization and Summary of Significant Accounting Policies, continued
For the three months ended June 30, 2010 and 2009, the following represents the Companys
weighted average fair value of options and warrants granted:
Weighted | ||||||||
Average | ||||||||
Fair Value | ||||||||
of | ||||||||
Options and | ||||||||
Period Ended: | Granted | Warrants | ||||||
June 30, 2010 |
36,800 | $ | 1.85 | |||||
June 30, 2009 |
21,000 | $ | 5.12 |
There were no warrants and 36,800 stock options granted to employees and directors during the
three months ended June 30, 2010 and 21,000 warrants and no stock options granted to employees and
directors during the three months ended June 30, 2009. In connection with the warrants and options
granted and the vesting of prior warrants issued, during the three months ended June 30, 2010 and
2009, the Company recorded total charges of $111,507 and $143,174, respectively, which have been
included in selling, general and administrative expenses in the accompanying unaudited condensed
consolidated statements of operations. The Company issues new shares from its authorized shares
upon exercise of warrants or options.
As of June 30, 2010, there was $392,120 of total unrecognized compensation cost related to
non-vested stock options and warrants which is expected to be recognized over a remaining weighted
average vesting period of 1.76 years.
There were no exercises of warrants and options during the three months ended June 30, 2010.
The aggregate intrinsic value of stock options and warrants exercised during the three months ended
June 30, 2009 was $60,690.
Equity Instruments Issued to Non-Employees for Acquiring Goods or Services
Issuances of the Companys common stock for acquiring goods or services are measured at the
fair value of the consideration received or the fair value of the equity instruments issued,
whichever is more reliably measurable. The measurement date for the fair value of the equity
instruments issued to consultants or vendors is determined at the earlier of (i) the date at which
a commitment for performance to earn the equity instruments is reached (a performance commitment
which would include a penalty considered to be of a magnitude that is a sufficiently large
disincentive for nonperformance) or (ii) the date at which performance is complete. When it is
appropriate for the Company to recognize the cost of a transaction during financial reporting
periods prior to the measurement date, for purposes of recognition of costs during those periods
the equity instrument is measured at the then-current fair values at each of those interim
financial reporting dates.
During the three months ended June 30, 2010, the Company granted an aggregate of 40,000
warrants to purchase shares of the Companys common stock at an exercise price of $1.89 to a
consultant for services to be rendered through March 31, 2011. Of the total warrants, 20,000
warrants vested upon issuance with a fair value of $36,090 and 20,000 warrants will vest based upon
attainment of certain deliverables throughout the year and will be valued accordingly at each
interim reporting date until the deliverables are completed. The Company recognized an aggregate of
$40,560 in expense related to these warrants for the period ended June 30, 2010.
15
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 2. Organization and Summary of Significant Accounting Policies, continued
Income Taxes
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to
taxable income in the years in which those temporary differences are expected to be recovered or
settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized
in income in the period that includes the enactment date. A valuation allowance is provided for
certain deferred tax assets if it is more likely than not that the Company will not realize tax
assets through future operations. The Company is a subchapter C corporation and files a federal
income tax return. The Company files separate state income tax returns for California and Nevada.
It is not anticipated that there will be a significant change in the unrecognized tax benefits over
the next 12 months.
Basic and Diluted Loss Per Share
Basic loss per common share is computed based on the weighted average number of shares
outstanding during the period. Diluted loss per share is computed by dividing net loss by the
weighted average shares outstanding assuming all dilutive potential common shares were issued.
In addition, in computing the dilutive effect of convertible securities, the numerator is
adjusted to add back the after-tax amount of interest, if any, recognized in the period associated
with any convertible debt.
For
the three months ended June 30, 2010 and 2009, the Company was in a loss position and the basic and
diluted loss per share are the same since the effect of stock options, warrants and convertible
notes payable on loss per share was anti-dilutive and thus not included in the diluted loss per
share calculation. The impact under the treasury stock method of dilutive stock options and
warrants and the if-converted method of convertible debt would have resulted in weighted average
common shares outstanding of 9,238,571 and 4,656,340 for the three month periods ended June 30,
2010 and 2009.
Segment Reporting
We currently operate in only one segment.
Recent Accounting Pronouncements
In February 2010, the
Financial Accounting Standards Board, or FASB, issued amended guidance on subsequent events. Under this amended
guidance, U.S. Securities and Exchange Commission, or SEC, filers are no longer required to
disclose the date through which subsequent events have been evaluated in originally issued and
revised financial statements. This guidance was effective immediately and we adopted these new
requirements upon issuance of this guidance.
In January 2010, the FASB issued updated standards related to additional requirements and
guidance regarding disclosures of fair value measurements. The guidance requires the gross
presentation of activity within the Level 3 fair value measurement roll forward and details of
transfers in and out of Level 1 and 2 fair value measurements. In addition, companies will be
required to disclose quantitative information about the inputs used in determining fair values. We
adopted these standards on April 1, 2010. The adoption did not have a
material impact on our unaudited condensed consolidated financial statements.
16
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 2. Organization and Summary of Significant Accounting Policies, continued
Fair Value Measurements
The Company determines the fair value of its derivative instruments using a three-level
hierarchy for fair value measurements which these assets and liabilities must be grouped, based on
significant levels of observable or unobservable inputs. Observable inputs reflect market data
obtained from independent sources, while unobservable inputs reflect the Companys market
assumptions. This hierarchy requires the use of observable market data when available. These two
types of inputs have created the following fair-value hierarchy:
Level 1 Valuations based on unadjusted quoted market prices in active markets for identical
securities. Currently the Company does not have any items classified as Level 1.
Level 2 Valuations based on observable inputs (other than Level 1 prices), such as quoted prices
for similar assets at the measurement date; quoted prices in markets that are not active; or other
inputs that are observable, either directly or indirectly.
The Company classifies its restricted cash balance as a Level 2 item. At June 30, 2010 and
March 31, 2010 the balance in the restricted cash account was $90,630 and $90,404, respectively.
Level 3 Valuations based on inputs that are unobservable and significant to the overall fair
value measurement, and involve management judgment. The Company uses the Black-Scholes option
pricing model to determine the fair value of the instruments. If the inputs used to measure fair
value fall in different levels of the fair value hierarchy, a financial securitys hierarchy level
is based upon the lowest level of input that is significant to the fair value measurement.
The following table presents the Companys warrants measured at fair value on a recurring
basis as of June 30, 2010 and March 31, 2010 classified using the valuation hierarchy:
Level 3 | Level 3 | |||||||
Carrying | Carrying | |||||||
Value | Value | |||||||
June 30, | March 31, | |||||||
2010 | 2010 | |||||||
(unaudited) | ||||||||
Warrants |
$ | 217,835 | $ | 334,363 | ||||
The following table provides a reconciliation of the beginning and ending balances for the
Companys derivative liabilities measured at fair value using Level 3 inputs:
Level 3 | Level 3 | |||||||
Carrying Value | Carrying Value | |||||||
2010 | 2009 | |||||||
Balance at April 1 |
$ | 334,363 | $ | | ||||
Cumulative effect of EITF 07-5 |
| 16,470,718 | ||||||
Issuance of warrants |
| 317,140 | ||||||
Issuance of convertible notes |
| 604,280 | ||||||
Conversions of notes |
| (593,303 | ) | |||||
Change in fair value, net |
(116,528 | ) | (3,134,298 | ) | ||||
Balance at June 30 |
$ | 217,835 | $ | 13,664,537 | ||||
17
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 3. Line of Credit
On November 5, 2007, the Company secured financing for a $200,000 one-year revolving line of
credit (the Line) secured by a $200,000 Certificate of Deposit with Bank of the West. On November
6, 2008, the Company secured a one-year renewal of the Line for a reduced amount of $100,000 which
is secured by a $100,000 Certificate of Deposit with Bank of the West. On October 19, 2009, the
Company secured a one-year renewal of the Line for a reduced amount of $90,000 which is secured by
a $90,000 Certificate of Deposit with Bank of the West. All borrowings under the revolving line of
credit bear variable interest based on either the prime rate plus 1.5% per annum (totaling 4.75% as of
June 30, 2010) or 5.0%, whichever is higher. The Company utilizes the funds advanced from the Line
for capital equipment purchases to support the commercialization of the Companys CryoPort Express®
One-Way Shipper. As of June 30, 2010 and March 31, 2010, the outstanding balance of the Line was
$90,375 and $90,388, respectively, including accrued interest of $375 and $388, respectively.
During the three months ended June 30, 2010 and 2009, the Company recorded interest expense of
$1,138 and $910, respectively, related to the Line. No funds were drawn against the Line during
the three months ended June 30, 2010 and 2009.
Note 4. Related Party Transactions
Related Party Notes Payable
As of June 30, 2010 and March 31, 2010, the Company had aggregate principal balances of
$979,500 and $1,009,500, respectively, in outstanding unsecured indebtedness owed to five related
parties, including four former members of the board of directors, representing working capital
advances made to the Company from February 2001 through March 2005. These notes bear interest at
the rate of 6% per annum and provide for aggregate monthly principal payments which began April 1,
2006 of $2,500, and which increased by an aggregate of $2,500 every nine months to a maximum of
$10,000 per month. As of June 30, 2010, the aggregate principal payments totaled $10,000 per
month. Any remaining unpaid principal and accrued interest is due at maturity on various dates
through March 1, 2015.
Related-party interest expense under these notes was $15,024 and $16,794 for the three months
ended June 30, 2010 and 2009, respectively. Accrued interest, which is included in related party
notes payable in the accompanying unaudited condensed consolidated balance sheets, related to these
notes amounted to $633,780 and $618,756 as of June 30, 2010 and
March 31, 2010, respectively. As of
June 30, 2010, the Company had not made the required payments under the related-party notes which
were due on April 1, May 1, and June 1, 2010. However, pursuant to the note agreements, the Company
has a 120-day grace period to pay missed payments before the notes are in default. On July 15,
2010, the Company paid the April 1 note payments due on these related party notes. Management
expects to continue to pay all payments due prior to the expiration of the 120-day grace periods.
18
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 4. Related Party Transactions, continued
Note Payable to Former Officer
In August 2006, Peter Berry, the Companys former Chief Executive Officer, agreed to convert
his deferred salaries to a long-term note payable. Under the terms of this note, the Company began
to make monthly payments of $3,000 to Mr. Berry in January 2007. Interest of 6% per annum on the
outstanding principal balance of the note began to accrue on
January 1, 2008. The loan and a portion of the accrued
interest was paid in March 2010 and the remaining accrued
interest of $11,996 was paid in August 2010. Interest expense related to this note was $2,376 for the
three months ended June 30, 2009. In February 2009, Mr. Berry resigned his position as Chief
Executive Officer and on July 30, 2009, Mr. Berry resigned his position from the Board.
Consulting agreement with Former Officer
On March 1, 2009, the Company entered into a Consulting Agreement with Peter Berry, the
Companys former Chief Executive Officer. Mr. Berry provided the Company with consulting services
as an independent contractor, for a ten (10) month period from March 1, 2009 through December 31,
2009, as an advisor to the Chief Executive Officer and the Board of Directors. Related-party
consulting fees for these services were $86,670 for the three months ended June 30, 2009.
Related party legal services
Since June 2005, the Company had retained the legal services of Gary C. Cannon, Attorney at
Law, for a monthly retainer fee. From June 2005 to May 2009, Mr. Cannon also served as the
Companys Secretary and a member of the Companys Board of Directors. Mr. Cannon continued to
serve as Corporate Legal Counsel for the Company and served as a member of the Advisory Board. In
December 2007, Mr. Cannons monthly retainer for legal services was increased from $6,500 per month
to $9,000 per month. The total amount paid to Mr. Cannon for retainer fees and out-of-pocket
expenses for the three months ended June 30, 2010 and 2009 was $0 and $27,000, respectively. At
June 30, 2010 and March 31, 2010, $0 and $7,788, respectively, of deferred board fees was included
in accrued compensation and related expenses. During the three months ended June 30, 2009, Mr.
Cannon was granted a total of 1,978 warrants with an average exercise price of $6.15 per share.
All warrants granted to Mr. Cannon were issued with an exercise price of greater than or equal to
the stock price of the Companys shares on the grant date. On May 4, 2009, Mr. Cannon resigned from
the Companys Board of Directors and in July 2009 Mr. Cannon was given 30 days notice that he was
terminated as the general legal counsel and advisor to the Company.
Consulting agreement with Officers
On July 29, 2009, the Board of Directors of the Company appointed Ms. Catherine M. Doll, a
consultant, to the offices of Chief Financial Officer, Treasurer and Assistant Corporate Secretary,
which became effective on August 20, 2009. Ms. Doll is the owner and chief executive officer of
The Gilson Group, LLC. The Gilson Group, LLC provided the Company financial and accounting
consulting services including, SEC and financial reporting including the filing of the S-1,
budgeting and forecasting and finance and accounting systems implementations and conversions.
Related-party consulting fees for all services provided by The Gilson Group, LLC, including a
monthly retainer for the Chief Financial Officer, were $144,833 and $0 for the three months ended
June 30, 2010 and 2009, respectively.
19
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 5. Convertible Notes Payable
The Companys convertible debenture balances are shown below:
June 30, | March 31, | |||||||
2010 | 2010 | |||||||
(unaudited) | ||||||||
October 2007 Debentures |
$ | 3,150,975 | $ | 3,150,975 | ||||
May 2008 Debentures |
79,593 | 79,593 | ||||||
3,230,568 | 3,230,568 | |||||||
Debt discount |
(606,544 | ) | (728,109 | ) | ||||
Total convertible debentures, net |
$ | 2,624,024 | $ | 2,502,459 | ||||
Short-term: |
||||||||
Current
portion of convertible debentures payable, net of discount of
$454,807 at June 30, 2010 and $0 at March 31, 2010 |
$ | 345,193 | $ | 200,000 | ||||
Long-term: |
||||||||
Convertible debentures payable, net of current portion and discount
of $151,737 at June 30, 2010 and $728,109 at March 31, 2010 |
2,278,831 | 2,302,459 | ||||||
Total convertible debentures, net |
$ | 2,624,024 | $ | 2,502,459 | ||||
The October 2007 and May 2008 (together referred to as the Debentures) are convertible into
shares of the Companys common stock at a price of $3.00 per share. The Debentures bear interest at 8%.
Future interest of $163,573 (in the aggregate) that accrues on the outstanding
principal balance from July 1, 2010 (the date to which accrued interest
was previously added to principal) to March 1, 2011 was added to the
principal balance of the debentures in February 2010, with a corresponding
increase to the debt discount which is amortized over the remaining life of the
debt. The Company is not obligated
to make any principal or additional interest payments until March 1, 2011 with respect to the outstanding
balances of the Debentures, at which time the Company will be obligated to start making monthly
principal and interest payments of $200,000 in the aggregate for a period of seventeen (17) months
with a final balloon payment due on August 1, 2012.
During the three months ended June 30, 2010 and 2009, the Company recognized an aggregate of
$121,565 and $2,268,690 in interest expense, respectively, due to amortization of debt discount
related to the warrants, beneficial conversion features and implied
interest associated with the Companys outstanding
convertible notes payable.
20
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 6 Derivative Liabilities
In accordance with current accounting guidance, certain of the Companys outstanding warrants
to purchase shares of common stock and embedded conversion features in convertible notes payable
previously treated as equity are no longer afforded equity treatment because these instruments have
reset or ratchet provisions in the event the Company raises additional capital at a lower price,
among other adjustments. As such, the fair value of these common stock purchase warrants and
embedded conversion features are treated as derivative liabilities. Changes in fair value are
recorded as non-operating, non-cash income or expense at each reporting date. If the fair value of
the derivatives is higher at the subsequent balance sheet date, the Company will record a
non-operating, non-cash charge. If the fair value of the derivatives is lower at the subsequent
balance sheet date, the Company will record non-operating, non-cash income. As of June 30, 2010
and March 31, 2010 the Company had derivative warrant liabilities of $217,835 and $334,363,
respectively.
During the three months ended June 30, 2010 and 2009, the Company recognized aggregate gains
of $116,528 and $3,134,298, respectively, due to the change in fair value of its derivative
instruments. See Note 2 Organization and Summary of Significant Accounting Policies Fair
Value Measurements, for the components of changes in derivative liabilities.
The Companys common stock purchase warrants do not trade in an active securities market, and
as such, the Company estimated the fair value of these warrants using the Black-Scholes option
pricing model using the following assumptions:
June 30, | March 31, | |||
2010 | 2010 | |||
Expected dividends |
| | ||
Expected term (in years) |
3.75 4.22 | 3.50 5.00 | ||
Risk-free interest rate |
1.00% 1.79% | 1.42% 2.69% | ||
Expected volatility |
186% 189% | 178% 204% |
Historical volatility was computed using daily pricing observations for recent periods that
correspond to the remaining term of the warrants, which had an original term of five years from the
date of issuance. The expected life is based on the remaining term of the warrants. The risk-free
interest rate is based on U.S. Treasury securities with a maturity corresponding to the remaining
term of the warrants.
21
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 7. Commitments and Contingencies
Lease Commitments
On July 2, 2007, the Company entered into a lease agreement with Viking Investors Barents
Sea, LLC (Lessor) for a building with approximately 11,881 square feet of manufacturing and office
space located at 20382 Barents Sea Circle, Lake Forest, CA, 92630. The lease agreement is for a
period of two years with renewal options for three, one-year periods, beginning September 1, 2007.
The lease required base lease payments of approximately $10,000 per month plus operating expenses.
In connection with the lease agreement, the Company issued to the lessor a warrant to purchase
1,000 shares of common stock at an exercise price of $15.50 per share for a period of two years,
valued at $15,486 as calculated using the Black Scholes option pricing model. The assumptions used
under the Black-Scholes pricing model included: a risk free rate of 4.75%; volatility of 293%; an
expected exercise term of 5 years; and no annual dividend rate. The Company capitalized and
amortized the value of the warrant over the life of the lease and recorded the unamortized value of
the warrant in other long-term assets. For the three months ended June 30, 2010 and 2009, the
Company amortized $0 and $1,776, respectively. On August 24, 2009, the Company entered into the
second amendment to the lease for its manufacturing and office space. The amendment extended the
lease for twelve months from the end of the existing lease term with a right to cancel the lease
with a minimum of 120 day written notice at anytime as of November 30, 2009. In June 2010, Company
entered into the third amendment to the lease for its manufacturing and office space. The amendment
extended the lease for sixty months commencing July 1, 2010 with a right to cancel the lease with a
minimum of 120 day written notice at anytime as of
December 31, 2012 and adjusted the base lease
payments to a range over the life of the agreement of $7,010 per
month to $8,911 per month plus operating expenses.
On April 15, 2010, the Company entered into office service agreements with Regus Management
Group, LLC (Lessor) for five (5) executive offices located at 402 West Broadway, San Diego, CA
92101. The office service agreements are for periods ranging from 3 to 7 months ending October 31,
2010. The office service agreements require aggregate base lease payments of approximately $5,100
per month.
Total rental expense was approximately $46,000 and $43,000 for the three months ended June 30,
2010 and 2009, respectively.
Litigation
The Company may become a party to product litigation in the normal course of business. The
Company accrues for open claims based on its historical experience and available insurance
coverage. In the opinion of management, there are no legal matters involving the Company that would
have a material adverse effect upon the Companys financial condition or results of operations.
Indemnities and Guarantees
The Company has made certain indemnities and guarantees, under which it may be required to
make payments to a guaranteed or indemnified party, in relation to certain actions or transactions.
The guarantees and indemnities do not provide for any limitation of the maximum potential future
payments the Company could be obligated to make. Historically, the Company has not been obligated
nor incurred any payments for these obligations and, therefore, no liabilities have been recorded
for these indemnities and guarantees in the accompanying unaudited condensed consolidated balance
sheets.
The Company indemnifies its directors, officers, employees and agents, as permitted under the laws
of the States of California and Nevada. In connection with its facility lease, the Company has
indemnified its lessor for certain claims arising from the use of the facility. The duration of the
guarantees and indemnities varies, and is generally tied to the life of the agreement.
In connection with the Companys agreement with FedEx pursuant to which the Company leases to FedEx its
cryogenic shippers, the Company has agreed to indemnify and hold harmless FedEx, its directors, officers,
employees and agents from and against any and all claims, demands, causes of action, losses, damages, judgments,
injuries and liabilities, including payment of attorneys fees. In addition, the Company has agreed to
indemnify, defend and hold harmless FedEx, its Affiliates (including the corporate patent company),
directors, officers, employees and agents from and against any and all Claims by third parties based
on an allegation that the use of the Company's shippers infringes on any United States or foreign
intellectual property right of such third parties, including any potential royalty payments and other
costs and damages, reasonable attorneys' fees and out-of-pocket expenses reasonably incurred by FedEx.
The duration of these indemnities survive the termination or expiration of the agreement.
22
Table of Contents
CRYOPORT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
For the Three Months Ended June 30, 2010 and 2009
Note 8. Equity
Common Stock
In April 2010, the Company issued 13,636 shares of unrestricted common stock in lieu of fees
paid to a consultant for services incurred in fiscal year 2010 pursuant to the Companys Form S-8
filed on April 27, 2010. These shares were issued at a value of $1.76 per share for a total cost
of $23,999 which was included in accounts payable and selling, general and administrative as of and
for the year ended March 31, 2010.
Warrants and Options
In May 2010, the Company granted 40,000 warrants to a consultant to purchase shares of the
Companys common stock with an exercise price of $1.89. Of the 40,000 warrants, 20,000 warrants
with a fair value of $36,030 vested upon issuance and the remaining 20,000 shares vest upon
completion of certain key milestones throughout the year (see Note 2).
During the three months ended June 30, 2010, a total of 36,800 stock options to purchase
shares of the Companys common stock with a weighted average fair value of $1.85 per share were
granted to employees and directors (see Note 2).
Note 9. Subsequent Events
On August 20, 2010, the Company
completed a private placement to institutional and accredited
investors resulting in the issuance of units consisting of 4,574,573 shares of common stock and
warrants to purchase 4,574,573 shares of common stock at an exercise
price of $0.77, for gross cash proceeds of $3,202,201 and net cash proceeds of $2,945,822. Each unit consisting of one share, together
with one warrant to purchase one share, was priced at $0.70. Certain investors that had invested
in the Companys public offering that was completed on February 25, 2010 were issued additional
warrants with the same terms to purchase an aggregate of 445,001 shares of common stock in connection with this private
placement. The warrants are immediately exercisable and have a term
of five years. Approximately $3,000,000 of the gross cash proceeds were disbursed from escrow on
August 20, 2010, with the balance expected to be disbursed within five business days. The Company is
obligated to file a registration statement with the SEC registering the resale of the shares of
common stock issued to the investors and the shares of common stock underlying the warrants issued
to the investors within sixty (60) days following the close of the transaction.
23
Table of Contents
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
In this Form 10-Q the terms CryoPort, Company and similar terms refer to CryoPort, Inc., and
its wholly owned subsidiary CryoPort Systems, Inc.
SAFE HARBOR FOR FORWARD LOOKING STATEMENTS:
THE COMPANY HAS MADE SOME STATEMENTS IN THIS FORM 10-Q, INCLUDING SOME UNDER MANAGEMENTS
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, AND ELSEWHERE, WHICH ARE
FORWARD-LOOKING STATEMENTS. THESE STATEMENTS MAY DISCUSS THE COMPANYS FUTURE EXPECTATIONS,
CONTAIN PROJECTIONS OF ITS PLAN OF OPERATION OR FINANCIAL CONDITION OR STATE OTHER FORWARD-LOOKING
INFORMATION. IN THIS FORM 10-Q, FORWARD-LOOKING STATEMENTS ARE GENERALLY IDENTIFIED BY WORDS SUCH
AS ANTICIPATE, PLAN, BELIEVE, EXPECT, ESTIMATE, AND THE LIKE. FORWARD-LOOKING STATEMENTS
INVOLVE FUTURE RISKS AND UNCERTAINTIES, AND THERE ARE FACTORS THAT COULD CAUSE ACTUAL RESULTS OR
PLANS TO DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY THE STATEMENTS. THE FORWARD LOOKING
INFORMATION IS BASED ON VARIOUS FACTORS AND IS DERIVED USING NUMEROUS ASSUMPTIONS. A READER,
WHETHER INVESTING IN THE COMPANYS SECURITIES OR NOT, SHOULD NOT PLACE UNDUE RELIANCE ON THESE
FORWARD-LOOKING STATEMENTS, WHICH APPLY ONLY AS OF THE DATE OF THIS FORM 10-Q. IMPORTANT FACTORS
THAT MAY CAUSE ACTUAL RESULTS TO DIFFER FROM PROJECTIONS INCLUDE, BUT ARE NOT LIMITED TO, THE
FOLLOWING:
| THE SUCCESS OR FAILURE OF MANAGEMENTS EFFORTS TO IMPLEMENT THE
COMPANYS PLAN OF OPERATIONS; |
| THE COMPANYS ABILITY TO FUND ITS OPERATING EXPENSES; |
| THE COMPANYS ABILITY TO COMPETE WITH OTHER COMPANIES THAT HAVE A
SIMILAR PLAN OF OPERATION; |
| THE EFFECT OF CHANGING ECONOMIC CONDITIONS IMPACTING THE COMPANYS
PLAN OF OPERATION; AND |
| THE COMPANYS ABILITY TO MEET THE OTHER RISKS AS MAY BE DESCRIBED IN
ITS FUTURE FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION. |
THE COMPANY UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE OR REVISE ANY FORWARD-LOOKING STATEMENTS,
WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.
General Overview
The following management discussion and analysis of the Companys financial condition and
results of operations (MD&A) should be read in conjunction with the condensed consolidated
balance sheet as of June 30, 2010 (unaudited) and the consolidated balance sheet as of March 31,
2010 (audited) and the related unaudited condensed consolidated statements of operations for the
three months ended June 30, 2010 and 2009, the unaudited condensed consolidated statements of cash
flows for the three months ended June 30, 2010 and 2009 and the related notes thereto (see Item 1.
Financial Statements) as well as the audited consolidated financial statements of the Company as of
March 31, 2010 and 2009 and for the years then ended included in the Companys Annual Report on
Form 10-K for the year ended March 31, 2010. The Company cautions readers that important facts and
factors described in this MD&A and elsewhere in this document sometimes have affected, and in the
future could affect, the Companys actual results, and could cause the Companys actual results
during fiscal year 2011 and beyond to differ materially from those expressed in any forward-looking
statements made by, or on behalf of the Company.
We are a provider of an innovative cold chain frozen shipping system dedicated to providing
superior, affordable cryogenic shipping solutions that ensure the safety, status and temperature,
of high value, temperature sensitive materials. We have developed cost effective reusable
cryogenic transport containers (referred to as shippers) capable of transporting biological,
environmental and other temperature sensitive materials at temperatures below 0° Celsius. These
dry vapor shippers are one of the first significant alternatives to dry ice shipping and achieve
10-plus day holding times compared to one to two day holding times with dry ice.
Our value proposition comes from providing both safe transportation and an environmentally
friendly, long lasting shipper, and through our value added services that offer a simple,
hassle-free solution for our customers. These value-added services include an internet-based web
portal that enables the customer to initiate scheduling, shipping and tracking of the progress and
status of a shipment, and provides in-transit temperature and custody transfer monitoring services
of the shipper. The CryoPort service also provides a fully ready charged shipper containing all
freight bills, customs documents and regulatory paperwork for the entire journey of the shipper to
our customers at their pick up location.
24
Table of Contents
Our principal focus has been the further development and commercial launch of CryoPort
Express® Portal, an innovative IT solution for shipping and tracking high-value specimens through
overnight shipping companies, and our CryoPort Express® Shipper, a dry vapor cryogenic shipper for
the transport of biological and pharmaceutical materials. A dry vapor cryogenic shipper is a
container that uses liquid nitrogen in dry vapor form, which is suspended inside a vacuum insulated
bottle as a refrigerant, to provide storage temperatures below minus 150° Celsius. The dry vapor
shipper is designed using innovative, proprietary, and patented technology which prevents spillage
of liquid nitrogen and pressure build up as the liquid nitrogen evaporates. A proprietary foam
retention system is employed to ensure that liquid nitrogen stays inside the vacuum container, even
when placed upside-down or on its side, as is often the case when in the custody of a shipping
company. Biological specimens are stored in a specimen chamber, referred to as a well, inside
the container and refrigeration is provided by harmless cold nitrogen gas evolving from the liquid
nitrogen entrapped within the foam retention system surrounding the well. Biological specimens
transported using our cryogenic shipper can include clinical samples, diagnostics, live cell
pharmaceutical products (such as cancer vaccines, semen and embryos, infectious substances) and
other items that require and/or are protected through continuous exposure to frozen or cryogenic
temperatures (below minus 150° Celsius).
During our early years, our limited revenue was derived from the sale of our reusable product
line. Our current business plan focuses on per-use leasing of the shipping container and
added-value services that will be used by us to provide an end-to-end and cost-optimized shipping
solution to life science companies moving pharmaceutical and biological samples in clinical trials
and pharmaceutical distribution.
We have incurred losses since inception and had an accumulated deficit of $47,272,613 through
June 30, 2010.
Results of Operations
Three months ended June 30, 2010 compared to three months ended June 30, 2009:
Revenues. Net revenues were $151,460 for the three months ended June 30, 2010, as compared to
$13,703 for the three months ended June 30, 2009. The increase of $137,757 (1,005%) is a result of
the current business plan focusing on per-use leasing of the shipping container and added-value
services that will be used by us to provide an end-to-end and cost-optimized shipping solution to
life science companies moving pharmaceutical and biological samples in clinical trials and
pharmaceutical distribution.
Gross loss and cost of revenues. Gross loss for the three months ended June 30, 2010 was
160% of net revenues, or $243,075 as compared to 989% of net revenues, or $135,474, for the three months ended June 30, 2009. The
decrease in gross loss for the three months ended June 30, 2010, as compared to the three months
ended June 30, 2009 is primarily the result of the increase in revenues from per-use leasing of the
shipping containers. The increase in cost of revenues is primarily the result of increased net
revenues. The cost of revenues exceeded net revenues due to fixed manufacturing costs and plant underutilization.
Selling, general and administrative expenses. Selling, general and administrative expenses
were $943,265 for the three months ended June 30, 2010, as compared to $728,309 for the three
months ended June 30, 2009. The $214,956 increase reflects the addition of four employees, additional
facilities, upgrades in internal information technology, and the promotional activities associated
with the launch of the per-use leasing of the shipping container and added-value services.
Research and development expenses. Research and development expenses were $122,121 for the
three months ended June 30, 2010, as compared to $87,725 for the three months ended June 30, 2009.
The increase in research and development expenses of $34,396 is due primarily to the costs
associated with the continued development of the Internet-based web portal that enables the
customer to initiate and monitor the progress of a shipment.
Interest expense. Interest expense was $138,708 for the three months ended June 30, 2010, as
compared to $2,533,197 for the three months ended June 30, 2009. Interest expense for the three
months ended June 30, 2010 included accrued interest on our Related Party notes payable ($15,024),
and amortization of the debt discount ($121,165). Interest expense for the three months ended June
30, 2009 included accrued interest on our Related Party notes payable ($16,794), amortization of
financing fees ($7,904), amortization of the debt discount ($2,268,690) and $137,246 of accrued
interest, primarily related to the convertible debentures issued in October 2007, May 2008 and
March and May 2009 Private Placement Debentures.
Interest income. Interest income was $3,437 for the three month period ended June 30, 2010 as
compared to $1,481 for the three month period ended June 30, 2009. Current interest income
included the impact of increased cash balances related to the funds received in connection with the
February 25, 2010 public offering.
Change in fair value of derivative liabilities. The gain on the change in fair value of
derivative liabilities was $116,528 for the three months ended June 30, 2010, compared to a gain of
$3,134,298 for the three months ended June 30, 2009. The gain of $116,528 for the three months
ended June 30, 2010 was the result of a decrease in the value of our warrant derivatives, due
primarily to a decrease in our stock price. The gain of $3,134,298 for the three months ended June
30, 2009, which was the result of a decrease in the value of our warrant derivatives and the
embedded conversion feature derivatives related to our debt, was due primarily to a decrease in our
stock price. On April 1, 2009 we adopted a new accounting principle, which resulted in a
reclassification of the fair value of our warrants and embedded conversion features from
equity to derivative liabilities that are marked to fair value at each reporting period.
25
Table of Contents
Net loss. As a result of the factors described above, net loss for the three months ended June
30, 2010 increased by $979,081 to $1,328,804 or ($0.16) per share compared to a net loss of
$349,723 or ($0.08) per share for the three months ended June 30, 2009.
Liquidity and Capital Resources
As of June 30, 2010, the Company had cash and cash equivalents of $2,097,202 and working
capital of $593,908. The Companys working capital at June 30, 2010 included $217,835 of
derivative liabilities, the balance of which represented the fair value of warrants issued to
consultants and convertible note holders which were reclassified from equity during 2009. As of March 31, 2010, the Company had
cash and cash equivalents of $3,629,886 and working capital of $1,994,934. Historically, we have
financed our operations primarily through sales of our debt and equity securities. Since March
2005 through June 2010, we have received net proceeds of approximately $15.7 million from sales of our common stock
and the issuance of promissory notes, warrants and debt. As discussed in Note 9 of the accompanying
unaudited consolidated financial statements, pursuant to a private placement of its securities on
August 20, 2010, the Company received an additional $2,775,595
in net cash proceeds with a balance of $170,227 due to be received within five business days.
For the three months ended June 30, 2010, we used $1,247,452 of cash for operations primarily
as a result of the net loss of $1,328,804 including a non-cash gain of $116,528 due to the change in
valuation of our derivative liabilities and non-cash expenses of $121,565 and $152,067 due to discount
amortization related to our convertible debt instruments and the fair value of stock options and warrants, respectively. Offsetting the cash impact of our net
operating loss (excluding non-cash items) was an increase in accrued interest payable of $15,011
primarily due to our Related Party notes payable and a decrease in accounts payable of $205,513 due
primarily to the payment of S-1 expenses incurred in fiscal year 2010.
Net cash used in investing activities totaled $255,232 during the three months ended June 30,
2010, and was attributable to the purchase of property and equipment of $210,851 and the purchase
of intangible assets of $44,381.
Net cash used in financing activities totaled $30,000 during the three months ended June 30,
2010, and resulted from payments on our related party notes payable.
As discussed in Note 2 of the accompanying unaudited condensed consolidated financial statements, there
exists substantial doubt regarding our ability to continue as a going concern. We will need to
raise additional capital through one or more methods, including but not limited to issuing
additional equity, in order to fund our working capital needs and complete the commercial launch of
our CryoPort Express® System. On February 25, 2010 we completed a public offering for net proceeds
of approximately $3,742,097. As a result of this recent public offering, we had an aggregate cash
and cash equivalents balance of $2,097,202 as of June 30, 2010. As discussed in Note 9 of the
accompanying unaudited condensed consolidated financial statements, pursuant to a private placement of its
securities on August 20, 2010, the Company received an
additional $2,775,595 in net cash proceeds with a balance of $170,227
due to be received within five business days. The Company will use these amounts to fund
the working capital required for minimal operations including limited inventory build up as well as
limited sales efforts to advance the our commercialization of CryoPort Express® Shippers until
additional capital is obtained. Management has estimated that cash on hand as of June 30, 2010
plus the additional cash from the private placement, will be sufficient to allow us to continue our
operations only into the third quarter of fiscal 2011, and recognizes that we must obtain
additional capital for the achievement of sustained profitable operations. Managements plans
include obtaining additional capital through equity and debt funding sources; however, no assurance
can be given that additional capital, if needed, will be available when required or upon terms
acceptable to us.
26
Table of Contents
Recent Accounting Pronouncements
In February 2010, the FASB issued amended guidance on subsequent events. Under this amended
guidance, U.S. Securities and Exchange Commission, or SEC, filers are no longer required to
disclose the date through which subsequent events have been evaluated in originally issued and
revised financial statements. This guidance was effective immediately and we adopted these new
requirements upon issuance of this guidance.
In January 2010, the FASB issued updated standards related to additional requirements and
guidance regarding disclosures of fair value measurements. The guidance requires the gross
presentation of activity within the Level 3 fair value measurement roll forward and details of
transfers in and out of Level 1 and 2 fair value measurements. In addition, companies will be
required to disclose quantitative information about the inputs used in determining fair values. We
adopted these standards on April 1, 2010. The adoption did not have a
material impact on our unaudited condensed consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Changes in United States interest rates would affect the interest earned on our cash and cash
equivalents and interest expense on our revolving credit facility.
A primary objective of our investment activities is to preserve principal
while at the same time maximizing the income we receive from our investments without significantly
increasing risk. Based on our overall cash and cash equivalents interest rate exposure at as of June 30, 2010,
a near-term change in interest rates, based on historical movements, would not have a material
adverse effect on our financial position or results of operations.
All outstanding amounts under our Revolving Credit Facility bear interest at a variable rate
equal to the lenders prime rate plus a margin of 1.50% or 5.0%, whichever is higher.
As of June 30, 2010, we had $90,375 outstanding under our Revolving Credit Facility. The interest rate at
June 30, 2010 was 5.0%.
Accordingly, we would not expect our operating results or cash flows
to be affected to any significant degree by the effect of a near term change in interest rates.
The above only incorporates those exposures that existed as of June 30, 2010, and does not
consider those exposures or positions which could arise after that date. If we diversify our
investment portfolio into securities and other investment alternatives, we may face increased risk
and exposures as a result of interest risk and the securities markets in general.
27
Table of Contents
Item 4T. Controls and Procedures
Evaluation of Disclosure Controls and Procedures.
The Company carried out an evaluation under the supervision and with the participation of the
Companys management, including the Companys Chief Executive Officer (CEO) and our Chief
Financial Officer (CFO), of the effectiveness of the Companys disclosure controls and procedures
(as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended
(the Exchange Act)). Based upon that evaluation, the CEO and CFO concluded that as of June 30,
2010, our disclosure controls and procedures were effective in timely alerting them to the material
information relating to the Company (or the Companys consolidated subsidiaries) required to be
included in the Companys periodic filings with the SEC, subject to the various limitation on
effectiveness set forth below under the heading LIMITATIONS ON THE EFFECTIVENESS OF INTERNAL
CONTROLS, such that the information relating to the Company, required to be disclosed in SEC
reports (i) is recorded, processed, summarized and reported within the time periods specified in
SEC rules and forms, and (ii) is accumulated and communicated to the Companys management,
including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.
Changes in internal control over financial reporting.
Our principal executive officer and principal financial officer also evaluated whether any
change in our internal control over financial reporting, as such term is defined under Rules
13a-15(f) and 15d-15(f) promulgated under the Exchange Act, occurred during our most recent fiscal
quarter covered by this report that has materially affected, or is likely to materially affect, our
internal control over financial reporting.
LIMITATIONS ON THE EFFECTIVENESS OF INTERNAL CONTROLS
The Companys management, including the CEO and CFO, does not expect that our disclosure
controls and procedures on our internal control over financial reporting will necessarily prevent
all fraud and material error. An internal control system, no matter how well conceived and
operated, can provide only reasonable, not absolute, assurance that the objectives of the control
system are met. Further, the design of the control system must reflect the fact that there are
resource constraints, and the benefits of controls can provide absolute assurance that all control
issues and instances of fraud, if any, within the Company have been detected. These inherent
limitations include the realities that judgments in decision-making can be faulty, and that
breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented
by the individual acts of some persons, by collusion of two or more people, or by management
override of the internal control. The design of any system of controls also is based in part upon
certain assumptions about the likelihood of future events, and there can be no assurance that any
design will succeed in achieving its stated goals under all potential future conditions. Over time,
control may become inadequate because of changes in conditions, and/or the degree of compliance
with the policies or procedures may deteriorate.
28
Table of Contents
PART II OTHER INFORMATION
Item 1. Legal Proceedings
None
Item 2. Unregistered Sales of Equity Securities
In May 2010,
the Company granted 40,000 warrants to a consultant to purchase shares of the Companys
common stock with an exercise price of $1.89. Of the 40,000 warrants, 20,000 warrants vested
upon issuance and the remaining 20,000 shares vest upon completion of certain key milestones
throughout the year.
The issuance of the
securities of the Company in the above transaction were deemed to be exempt from registration
under the Securities Act of 1933 by virtue of Section 4(2) thereof or Regulation D promulgated
there under, as a transaction by an issuer not involving a public offering. With respect to
the transaction listed above, no general solicitation was made by either the Company or any
person acting on the Companys behalf; the securities sold are subject to transfer
restrictions; and the certificates for the shares contain an appropriate legend stating that such
securities have not been registered under the Securities Act of 1933 and may not be offered or
sold absent registration or pursuant to an exemption there from.
Item 3. Defaults Upon Senior Securities
None
Item 4. [Removed and Reserved.]
None
Item 5. Other Information
None
29
Table of Contents
Item 6. Exhibits
Exhibit Index
31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|||
31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|||
32.1 | Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of the
Sarbanes-Oxley Act of 2002. |
30
Table of Contents
SIGNATURES
In accordance with the requirements of the Exchange Act, the Registrant caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
CryoPort, Inc. |
||||
Dated: August 20, 2010 | By: | /s/ Larry G. Stambaugh | ||
Larry G. Stambaugh, Chairman, | ||||
Chief Executive Officer | ||||
Dated: August 20, 2010 | By: | /s/ Catherine M. Doll | ||
Catherine M. Doll, Chief Financial Officer | ||||
(signed as both an officer duly authorized
to sign on behalf of the Registrant and principal financial officer and Chief Accounting Officer) |
31